Genetic Signatures Limited (ASX: GSS) held its 2017 Annual General Meeting on Tuesday 28 November 2017 at 11.00am (AEST).
Category Archives: ASX Announcements
Genetic Signatures have been invited to present at the 2017 ASM Tri-State Scientific Meeting & Parasitology Masterclass 22-25 September, Darwin, Australia.
Genetic Signatures Chief Scientific Officer (CSO) Dr. Doug Millar will be presenting the results on the development of a 3baseTM Flavivirus and Alphavirus EasyScreenTM Detection assay. The test allows for the detection of 17 of the most common flavivirus and alphavirus infections in the world, including dengue, West Nile virus, Zika, yellow fever virus, and chikungunya.
We invite you to hear Dr. Millar’s presentation at Tri-State Scientific Meeting & Parasitology Masterclass: Monday 25th September 2017 at 11:30 am (EST)
About ASM Tri-State Scientific Meeting & Parasitology Masterclass 2017: Tri-State meetings have been initiated and supported by ASM branches in SA, WA and NT for over 25 years. The aim of this meeting is to bring delegates together in an intimate and unique environment. Expect a varied and engaging scientific program presented by some of Australia’s top microbiologists.
The Parasitology Masterclass began with its inaugural meeting in Tasmania in 2009, this is the 6th Parasitology Masterclass, it aims to again provide an excellent blend of wet workshops, classroom teaching, and formal presentations.
Genetic Signatures Announces Regulatory Approval for Complete Enteric Product Suite in Australia and Europe and secures 3baseTM Patent in USA
GenomeWeb, the largest online newsroom focused on advanced molecular research tools, has featured Genetic Signatures and 3base™ technology, in an article about the company’s continued global market rollout of their existing and new suite of products. The new 3base™ multiplex PCR tests include an assay for detecting sexually transmitted infections and another that tests for all flaviviruses and alphaviruses. These assays complement Genetic Signatures’ tests already available which include assays for enteric and respiratory infections. The GenomeWeb article highlighted Genetic Signatures’ recent clinical trial of their new EasyScreenTM Flavivirus/Alphavirus Detection kit, which was presented at the infectious diseases conference, ECCMID, in April 2017 (Vienna, Austria). The article also discussed the ongoing global expansion strategy including the progress of regulatory approval in Australia and a CE-IVD marking of a number of products in the coming months.